<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00157274</url>
  </required_header>
  <id_info>
    <org_study_id>MF/SS</org_study_id>
    <nct_id>NCT00157274</nct_id>
  </id_info>
  <brief_title>Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome</brief_title>
  <official_title>Phase II Study of Alemtuzumab in Patients With Advanced Mycosis Fungoides/Sezary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Latin American Cooperative Onco-Haematology Group - Peru</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Latin American Cooperative Onco-Haematology Group - Peru</source>
  <brief_summary>
    <textblock>
      The investigators designed a compassionate basis phase II study for refractory/relapsed
      mycosis fungoides/Sezary syndrome consisting of alemtuzumab (Campath) for primary evaluation
      of overall response and time to relapse. Other goals to consider are toxicity and time to new
      therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  20 relapsed or refractory advanced mycosis fungoides/Sezary syndrome patients are
           scheduled with gradually escalated doses (3 mg, 10 mg , and 30 mg) on sequential days
           during the first week, followed by 30 mg three times a week until 12 weeks.

        -  Patients must have serology negative for human T-lymphotropic virus 1 (HTLV-1) and until
           three different regimens of chemotherapy.

        -  Follow up for one year after last cycle of alemtuzumab.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2005</start_date>
  <completion_date type="Anticipated">July 2008</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to relapse</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Event free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <enrollment>20</enrollment>
  <condition>Mycosis Fungoides</condition>
  <condition>Sezary Syndrome</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alemtuzumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Above 18 years old

          -  Eastern Cooperative Oncology Group (ECOG) 0-2

          -  Liver and renal function test less than twice upper label

          -  No active infection

          -  Written informed consent

          -  One to three regimens of previous chemotherapies

        Exclusion Criteria:

          -  Abnormal renal or hepatic function

          -  Mycosis fungoides/Sezary syndrome in transformation

          -  HIV +

          -  HTLV-1 +

          -  Pregnancy

          -  Lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brady E Beltran, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LACOGH - PERU</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia M Huamani, MD</last_name>
    <phone>511-2227020</phone>
    <email>juliahuamaniz@yahoo.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Schering Peruana S.A.</name>
      <address>
        <city>Lima</city>
        <zip>511</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesus A Arones, MD</last_name>
      <phone>99480078</phone>
      <email>alfredo_arones@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <results_reference>
    <citation>Lundin J, Hagberg H, Repp R, Cavallin-Ståhl E, Fredén S, Juliusson G, Rosenblad E, Tjønnfjord G, Wiklund T, Osterborg A. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003 Jun 1;101(11):4267-72. Epub 2003 Jan 23.</citation>
    <PMID>12543862</PMID>
  </results_reference>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 7, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>April 2, 2007</last_update_submitted>
  <last_update_submitted_qc>April 2, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2007</last_update_posted>
  <keyword>Alemtuzumab</keyword>
  <keyword>Mycosis fungoides</keyword>
  <keyword>Sezary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
    <mesh_term>Sezary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alemtuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

